Search clinical trials for: Ranibizumab combined macular laser

Total 178 results

Brandon G. Busbee, MD
Genentech, Inc.

Completed

Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST)

Macular Degeneration | Choroidal Neovascularization

United States
Russian Academy of Medical Sciences

Unknown

Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Russian Federation
Jose R. Reyes Memorial Medical Center

Completed

Efficacy of Fractional Carbon Dioxide Laser Combined With Platelet-rich Plasma

Striae Gravidarum

Philippines
OPKO Health, Inc.

Withdrawn

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) (CARBON)

Age Related Macular Degeneration
The New York Eye Cancer Center
Genentech, Inc.

Completed

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Radiation Retinopathy

United States
University Hospital, Bonn
Novartis

Completed

Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

Type 2 Idiopathic Macular Telangiectasia

Germany
Palmetto Retina Center, LLC

Completed

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (TREX-DME)

Diabetic Macular Edema

United States
Ameera Gamal Abdelhameed

Completed

Intravitreal Ranibizumab in Recurrent ROP

Retinopathy of Prematurity

Egypt
Universitätsklinikum Hamburg-Eppendorf

Recruiting

RFMN in Combination With 1927 nm Thulium Laser for Treating Photoaged Skin

Photoaging

Germany
PD. Dr. med. Armin Wolf
University Hospital, Bonn

Unknown

Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas (PEARL)

Central Retinal Vein Occlusion With Macular Edema
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RELATION)

Visual Impairment Due to Diabetic Macular Edema

Germany
University of California, Irvine
Beckman Laser Institute University of California Irvine

Completed

Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser

Vascular Lesion

United States
Ural State Medical University
Ural Institute of Cardiology; De Haar Research Foundation

Terminated

Ranibizumab and the Risk of Arterial Thromboembolic Events (RATE)

Coronary Artery Disease | Cerebrovascular Disorders | Age-related Macular Degeneration

Netherlands, Russian Federation
Mid-Atlantic Retina Consultations, Inc.

Completed

Photodynamic and Pharmacologic Treatment of CNV (PBS)

Macular Degeneration | Choroidal Neovascularization
Syneron Medical

Completed

Surgical Scar Treatment With the Pulsed Dye Laser in Combination With a CO2 Laser

Scars

United States
Ain Shams University

Completed

New Concepts in Diabetic Macular Edema (DME) (DME)

Diabetes Mellitus, With Complications
Dar El Oyoun Hospital
Cairo University

Completed

Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm. (RAM)

Retinal Artery Macroaneurysm

Egypt
Moorfields Eye Hospital NHS Foundation Trust
Novartis

Completed

Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation (LUCIDATE)

Diabetic Retinopathy

United Kingdom
Riphah International University

Completed

Combine Effects of Brunnstorm Movement Therapy and LLLT in Chronic Stroke Patient

Chronic Stroke

Pakistan
Opthea Limited

Completed

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, France, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom
Allergan

Completed

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration

United States, Italy, Australia, Israel, Germany, Austria, France, Switzerland
Novartis Pharmaceuticals

Completed

Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (PRIDE)

Proliferative Diabetic Retinopathy (PDR)

Germany
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital with Nanjing Medical University; Zhejiang Provincial...

Recruiting

Low Temperature Plasma Ablation Combined Lacrimal Duct Catheterization in the Treatment of Lacrimal Duct Obstructive

Lacrimal Duct Obstruction

China
Sun Yat-sen University

Completed

Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

China
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI)

Diabetes Mellitus | Diabetic Macular Edema

United States
McGill University Health Centre/Research Institute...

Unknown

Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration

Macular Degeneration | Visual Acuity

Canada
Derming SRL

Completed

Efficacy of an Antiage Aesthetic Treatment for the Middle and Inferior Third of the Face

Face Skin Laxity

Italy
The University of Hong Kong
National University Hospital, Singapore; Korea University; Kyungpook National... and other collaborators

Unknown

To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema (END-DME)

Diabetic Macula Edema

China
Zagazig University
Cairo University

Recruiting

Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity

Retinopathy of Prematurity Both Eyes

Egypt
Southern New England Retina Associates
Genentech, Inc.

Completed

Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease

Retinal Ischemia

United States
Hospital Hietzing

Completed

Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

Diabetic Retinal Edema

Austria
Rocky Mountain Retina Consultants
Genentech, Inc.

Completed

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

Diabetic Retinopathy | Diabetic Macular Edema

United States
Qena Faculty of medicine, South Valley University

Recruiting

Ranibizumab Versus Aflibercept for CRVO in Young Patients.

Non-Ischemic Central Retinal Vein Occlusion With Macular Edema

Egypt
Medical University of Vienna

Completed

Ranibizumab in Patients With Branch Retinal Vein Occlusion

Retinal Vein Occlusion

Austria
Kunming Tongren Hospital

Recruiting

SVF Combined With Functional Self-assembling Peptide Nanofiber Hydrogels in the Treatment of Spinal Cord Injury

Safety Issues

China
University of Malaya

Unknown

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Age Related Macular Degeneration

Malaysia
LUTRONIC Corporation

Unknown

Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema

Diabetic Macular Edema

Korea, Republic of
Aquinox Pharmaceuticals (Canada) Inc.

Completed

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study (DDI-COC)

Healthy Volunteer

Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (BRIGHTER)

Branch Retinal Vein Occlusion

Greece, Hungary, Australia, Spain, United Kingdom, Italy, Netherlands, Ireland, Portugal, France, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Novartis Pharmaceuticals

Completed

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) (UNRAVEL)

Neovacular Age-related Macular Degeneration

Taiwan, Thailand, Israel, Korea, Republic of, Philippines, Singapore, Malaysia
Kyoto University, Graduate School of Medicine

Recruiting

Cohort Study of the Clinical Course of Macular Diseases in Japanese

Macular Disease

Japan
Zagazig University

Completed

Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser in the Treatment of Acne Erythema

Acne Vulgaris

Egypt
University of Leipzig

Completed

Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT (RabOCT)

Branch Retinal Vein Occlusion

Germany
University of New Mexico
Genentech, Inc.

Completed

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

Pterygium

United States
Sun Yat-sen University

Unknown

Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Retinal Vein Occlusion | Treatment | Ranibizumab | Photocoagulation Burn to Retina

China
Moorfields Eye Hospital NHS Foundation Trust
Novartis

Completed

The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema

Uveitis Related Cystoid Macular Edema | Steroid-induced Glaucoma - Borderline

United Kingdom
Novartis Pharmaceuticals

Completed

A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (OLIMPIC)

Choroidal Neovascularization Secondary to Pathologic Myopia

Italy
University of California, San Diego
Genentech, Inc.

Withdrawn

Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT) | Nosebleeds
University Health Network, Toronto

Completed

Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing

Age Related Macular Degeneration

Canada
University of California, Irvine
Beckman Laser Institute University of California Irvine

Withdrawn

Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks

Port-Wine Stain

Search clinical trials for: Ranibizumab combined macular laser

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations